Within-Subject Comparison of Adipose Tissue Viability Following Liposuction

This study will evaluate and compare the quality of adipose (fat) tissue harvested using different liposuction technologies and aspiration methods. Each participant will serve as their own control, with paired fat samples collected from anatomically matched treatment areas. The study will evaluate adipocyte viability and other characteristics of the harvested tissue, including viable adipocyte density, stromal vascular fraction, metabolic activity, and fat composition. The goal of the study is to better understand how different liposuction technologies and aspiration methods affect the quality and characteristics of harvested adipose tissue.

Inclusion Criteria: * Male or female aged 30 to 65 years, inclusive. * Planned elective liposuction/body contouring procedure involving two or more anatomical areas (e.g., arms, abdomen, flanks, thighs, and/or back) with sufficient distribution to permit collection of paired adipose tissue samples from contralateral or anatomically matched treatment areas. * Investigator determines the subject is an appropriate candidate for the planned procedure and study participation. * Adequate adipose tissue is present to permit collection of required paired fat samples without impacting the planned surgical outcome. * Able to understand and sign the informed consent form. * Willing and able to comply with study requirements. * If applicable, female subjects of childbearing potential must have a negative urine pregnancy test on the day of procedure. Exclusion Criteria: * Prior liposuction or surgical intervention in the planned treatment areas that, in the opinion of the investigator, may affect adipose tissue characteristics or study assessments. * Prior treatment of the planned treatment areas with energy-based devices (e.g., ultrasound, radiofrequency, laser) that, in the opinion of the investigator, may affect adipose tissue characteristics or study assessments. * Significant skin laxity, fibrosis, scarring, or other abnormal tissue characteristics in the planned treatment areas that could impact fat harvest quality or comparability between sites. * Current smoker or use of nicotine-containing products within 4 weeks prior to the procedure. * Known metabolic or systemic conditions that may affect adipose tissue biology or wound healing, including but not limited to: * uncontrolled diabetes mellitus * significant vascular disease * connective tissue disorders * Use of medications known to significantly affect fat metabolism, tissue healing, or inflammatory response, including: * chronic systemic corticosteroids * immunosuppressive therapies * GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) within 4 weeks prior to the procedure * Active local or systemic infection at the time of the procedure. * Known coagulopathy or use of anticoagulant therapy that cannot be safely discontinued prior to surgery. * Pregnant or breastfeeding subjects. * Body mass index (BMI) outside the range of 20-35 kg/m², inclusive. * Inadequate adipose tissue volume or distribution to permit paired sample collection from contralateral or anatomically matched areas. * Participation in another interventional clinical study that, in the opinion of the investigator, could interfere with study endpoints. * Any condition that, in the opinion of the investigator, would make the subject unsuitable for participation or could confound study results.